Anti-BAFF therapy is now considered to be a main line of treatment in a subset of systemic lupus erythematosus patients, who exhibit a strong predisposition to premature atherosclerosis and heart attacks.32,33 The protective effect of BAFF inhibition in systemic lupus erythematosus has been attributed to its B cell–depleting effect. The gene discussed is TNFSF13B; the disease is atherosclerosis.